ImmunoGen, Inc. Appoints Richard J. Gregory, Ph.D. As EVP, Chief Scientific Officer; John M. Lambert, Ph.D. Named EVP, Distinguished Research Fellow

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced the appointment of Richard J. Gregory, Ph.D., as Executive Vice President, Research and Chief Scientific Officer (CSO), reporting to ImmunoGen President and CEO, Daniel Junius. Dr. Gregory will join the Company on January 5, 2015, at which time current CSO, John Lambert, Ph.D., will assume the position of Executive Vice President, Distinguished Research Fellow. Dr. Gregory brings to ImmunoGen deep scientific and research management experience, most recently serving as senior vice president and head of research for the Sanofi Genzyme Research & Development Center.

Help employers find you! Check out all the jobs and post your resume.